• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The systolic hypertension in the elderly pilot program: methodological issues.

作者信息

Furberg C D, Black D M

机构信息

Bowman Gray School of Medicine, Winston-Salem, NC 27103.

出版信息

Eur Heart J. 1988 Feb;9(2):223-7. doi: 10.1093/oxfordjournals.eurheartj.a062487.

DOI:10.1093/oxfordjournals.eurheartj.a062487
PMID:3350031
Abstract

The Systolic Hypertension in the Elderly Program (SHEP) Pilot Study was conducted to determine the feasibility of conducting a long-term placebo-controlled randomized clinical trial in elderly subjects. Enrolled in the study were 551 men and women between the ages of 60 and 90 years with isolated systolic hypertension (SBP greater than or equal to 160 mmHg and DBP less than 90 mmHg). The study showed that it is possible to recruit old and very old subjects into a clinical trial; the elderly are good compliers (drugs and follow-up visits), with some decline after the age of 80; control of blood pressure was accomplished in the large majority of patients; evaluation of side effects represents a potential problem as varied complaints increase with age thus creating difficulties in distinguishing those attributed to the study drug; and finally, cause-specific mortality is probably preferable to all-cause mortality as an end-point in prevention trials of antihypertensive regimens.

摘要

相似文献

1
The systolic hypertension in the elderly pilot program: methodological issues.
Eur Heart J. 1988 Feb;9(2):223-7. doi: 10.1093/oxfordjournals.eurheartj.a062487.
2
Systolic Hypertension in the Elderly Program, Pilot Study (SHEP-PS): morbidity and mortality experience.老年收缩期高血压计划,试点研究(SHEP-PS):发病率和死亡率情况。
J Hypertens Suppl. 1986 Dec;4(6):S21-3.
3
Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone.老年收缩期高血压计划(SHEP):氯噻酮的降压疗效
Am J Cardiol. 1985 Dec 1;56(15):913-20. doi: 10.1016/0002-9149(85)90404-7.
4
Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program.
J Gerontol. 1987 Sep;42(5):552-7. doi: 10.1093/geronj/42.5.552.
5
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.老年收缩期高血压计划(SHEP):一项关于单纯收缩期高血压的干预试验。SHEP合作研究组。
Clin Exp Hypertens A. 1989;11(5-6):973-89. doi: 10.3109/10641968909035386.
6
Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group.单纯收缩期高血压预防中风的随机临床试验的原理与设计。老年收缩期高血压计划(SHEP)合作研究组。
J Clin Epidemiol. 1988;41(12):1197-208. doi: 10.1016/0895-4356(88)90024-8.
7
Association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program.直立性高血压与老年收缩期高血压计划死亡率的相关性。
J Hum Hypertens. 2019 Oct;33(10):735-740. doi: 10.1038/s41371-019-0180-4. Epub 2019 Feb 25.
8
Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP).阿替洛尔和利血平对老年收缩期高血压计划(SHEP)中选定事件的影响。
Am J Hypertens. 1995 Dec;8(12 Pt 1):1147-53. doi: 10.1016/0895-7061(95)00363-0.
9
Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study.
Stroke. 1989 Jan;20(1):4-13. doi: 10.1161/01.str.20.1.4.
10
Predictors of cardiovascular events and mortality in the Systolic Hypertension in the Elderly Program pilot project.老年收缩期高血压计划试点项目中心血管事件和死亡率的预测因素
Am J Epidemiol. 1987 Sep;126(3):385-99. doi: 10.1093/oxfordjournals.aje.a114670.

引用本文的文献

1
Pharmacotherapy for hypertension in adults 60 years or older.60岁及以上成年人高血压的药物治疗
Cochrane Database Syst Rev. 2019 Jun 5;6(6):CD000028. doi: 10.1002/14651858.CD000028.pub3.
2
First-line drugs for hypertension.高血压一线用药。
Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD001841. doi: 10.1002/14651858.CD001841.pub3.
3
Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension.表观治疗抵抗性高血压患者中低药物治疗依从性的流行情况及其相关因素。
J Clin Hypertens (Greenwich). 2012 Oct;14(10):694-700. doi: 10.1111/j.1751-7176.2012.00690.x. Epub 2012 Aug 3.
4
Hypertension and medication adherence among African Americans: a potential factor in cardiovascular disparities.非裔美国人的高血压与药物依从性:心血管差异的一个潜在因素。
J Natl Med Assoc. 2003 Jan;95(1):28-9.
5
Epidemiology of hypertension in the elderly.老年人高血压的流行病学
Drugs Aging. 1992 May-Jun;2(3):222-42. doi: 10.2165/00002512-199202030-00006.
6
Clinical trials and clinical practice in the elderly. A focus on hypertension.
Drugs Aging. 1992 Mar-Apr;2(2):86-94. doi: 10.2165/00002512-199202020-00002.